Special Project in Non-Metastatic Castrate Resistant Prostate Cancer
Prostate Cancer Canada (PCC) has offered investigator-initiated Special Project in Non-Metastatic Castrate Resistant Prostate Cancer (NM-CRPC). This request for applications (RFA) solicited proposals from groups interested in combining various real world data sources (i.e. detailed chart review at prostate cancer centres with health administrative databases) to obtain high quality epidemiological data, outcomes and costs
among the population of prostate cancer patients in at least two provinces in Canada that together represent greater than 50% of the population.
The key objectives were:
- to obtain prevalence, incidence and survival probability estimates of prostate cancer, stratified by age and year of diagnosis from provincial cancer registries;
- to identify pathways leading to and factors associated with the target condition (NM-CRPC);
- to estimate annual incidence and prevalence of NM-CRPC, stratified probability of developing NM-CRPC and transition probabilities that characterize the prognosis from NM-CRPC to metastasis and end-of-life;
- to estimate health care resource use and costs for health states in the recurrent disease model.
up to $450,000 over 2 years